Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer

Official record

Identifier

NCT07733908

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

Posluma PET

Lead sponsor

Aditya Bagrodia

Target enrolment

22 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Not yet recruiting

First posted

Jul 29, 2026

Last updated on the registry

Aug 14, 2026

Age

18 Years

Sex

MALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Diagnosis: Histologically confirmed PCa.
2. Risk Profile: Intermediate-risk , organ-confined PCa
3. Eligibility for Focal Therapy: Determined to be an appropriate candidate for focal therapy based on clinical evaluation.
4. Age: 18 years or older.
5. Life Expectancy: Expected survival of at least 10 years.
6. Informed Consent: Ability to understand and willingness to sign the informed consent form.

Exclusion Criteria:

1. Previous Treatment: Prior treatment for PCa, including radiation therapy, chemotherapy, focal therapy, or androgen deprivation therapy.
2. Severe Comorbid Conditions: Presence of severe comorbid conditions that may interfere with study participation, such as uncontrolled cardiovascular, renal, hepatic, or metabolic diseases.
3. Contraindications to Imaging: Known hypersensitivity to components of the Posluma PSMA radiotracer, or inability to undergo PET or MRI imaging due to medical or anatomical constraints (e.g., severe claustrophobia, metallic implants incompatible with MRI).

Indexed under

Prostate Cancer